SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to heightened geopolitical tensions in the Strait of Hormuz, where reports of explosions and drone strikes have triggered intense community debate over potential supply disruptions and the future of the regional ceasefire. Investors are actively discussing whether these events indicate a return to a permanent high-risk shipping environment or if the recent price volatility is merely headline-driven noise masking underlying supply realities.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPath Technologies is attracting significant investor attention following a strong earnings report that showcased record backlog growth and a major expansion in manufacturing capacity for its BlackDiamond infrared optics. The community is focused on the company's strategic role in replacing constrained foreign materials like germanium with domestic alternatives for critical defense programs, drones, and space imaging systems.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors speculate on potential index inclusion and massive global expansion opportunities, leading to significant options activity and ongoing conflict between bullish retail sentiment and short sellers. The community is actively discussing the company's proprietary robotic manufacturing platform and anticipation for upcoming clinical and regulatory milestones.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors weigh strong fundamental performance and ongoing robotaxi expansion news against recent technical selling pressure. The community is actively debating the stock's significant undervaluation relative to analyst targets, with many traders closely monitoring institutional activity and political disclosures as potential catalysts for a move back toward historical support levels.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending amid ongoing geopolitical instability in the Middle East and concerns over persistent energy supply constraints. The community remains divided, with some investors betting on a long-term bull market due to low global reserves and infrastructure bottlenecks, while others focus on technical volatility and the potential for a regulatory-driven sell-off.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is experiencing significant upward momentum as investors rotate into healthcare, fueled by groundbreaking clinical data for its obesity pipeline and expanding market reach. The community remains focused on Eli Lilly's sustained leadership in the GLP-1 space, viewing its aggressive R&D and strategic diversification as key drivers for long-term growth.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Trulieve Cannabis Corp is trending as investors monitor the upcoming administrative hearing regarding the potential rescheduling of cannabis to Schedule III, a move widely anticipated to ease federal banking and regulatory burdens for the sector. Community sentiment remains focused on the company's fundamental performance and strategic expansion efforts as a major multi-state operator despite recent volatility.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is currently the center of active community debate regarding its valuation and long-term role as a pure-play optical leader in the AI infrastructure stack. While some investors are highlighting the stock's exposure to AI-driven bandwidth demand and its critical position in the optical transceiver market, others are expressing caution over its high price-to-earnings ratio and broader market volatility within the photonics sector.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant investor interest driven by a recent insider purchase from the CEO and a series of successful ABS financing deals that signal strong institutional confidence. While the community is actively debating the stock's volatility and its potential for a short squeeze, many are looking past near-term macro headwinds toward the company's consistent GAAP profitability and AI-driven infrastructure growth.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending as the community debates its aggressive expansion into the financial sector, specifically following announcements regarding a potential bank acquisition and its development of a high-throughput blockchain for global payment rails. While some investors remain cautious about volatility and the project's long-term execution, many supporters are actively accumulating, pointing to its notable partnerships and early infrastructure milestones as catalysts for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?

Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.

DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results

Equity

In the first part of the CIDP study, 75% of the initial group of patients showed meaningful improvement after receiving claseprubart, Dianthus said.

Why Is Dianthus Therapeutics Stock Trading Higher On Friday?

Dianthus reports 75% responder rate for claseprubart in CIDP, while analysts say Sanofi's riliprubart faces rising risks after MOBILIZE.read more...

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline...

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish...

Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Wedbush raised their price target on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an 'outperform' rating in a report on Wednesday...

Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts...

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +27.04% and -15.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics (DNTH) to Release Earnings on Monday

Dianthus Therapeutics (NASDAQ:DNTH) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-dianthus-therapeutics-inc-stock...

Short Interest in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Decreases By 27.6%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling...

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Dianthus Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.85	--	--	N/A
Q1 '26	-$1.06	-$0.85	20.01%	BEAT
Q4 '25	-$1.08	-$1.43	-32.92%	MISSED
Q3 '25	-$0.87	-$0.97	-11.82%	MISSED
Q2 '25	-$0.87	-$0.88	-0.95%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

DNTHDianthus Therapeutics Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest DNTH News